Isomorphic Labs has raised a $5 billion Series C financing round to scale its AI drug-design engine and move therapeutic candidates towards clinical trials. The company did not state a valuation.
In a release dated 17 November 2026 at 12:17 GMT, the London-based firm, which describes itself as an AI company focussed on designing and developing new medicines, said the round was co-led by Greenoaks and Sequoia Capital, alongside Andreessen Horowitz (a16z) and several other new investors, “with continued significant investment from Alphabet.” All existing investors also took part: Thrive Capital, MGX, GV, CapitalG, Temasek and the UK Sovereign AI Fund. A same-day post on the company’s own site repeats those terms and points readers to the release.
The company said it is scaling its proprietary drug design engine, IsoDDE, and a therapeutic-candidate pipeline designed with AI. IsoDDE, it said, unifies a suite of foundational simulation models that work across multiple therapeutic areas and drug modalities, and explores chemical space so its team can design and refine molecules. Combined with “proprietary agents that navigate and reason over highly complex biological systems,” those models are, in the company’s account, already translating into preclinical results for internal programmes in oncology and immunology, and with partners, “setting the stage for clinical entry.”
Proceeds, the release said, will go to maturing IsoDDE, expanding into new biology, building a partner ecosystem around mechanistic disease biology, and constructing the “global infrastructure required to power the future of AI-led bioengineering,” including “scalable AI-first translational and clinical development infrastructure as it advances its drug candidates to clinical trials.”
Sir Demis Hassabis, founder and chief executive, said: “When we founded Isomorphic, our conviction was that biology could be understood and modelled at the most fundamental molecular level and radically accelerated through AI. Our drug design engine is generating molecules with unprecedented precision and speed. This round enables us to accelerate our progress: building foundational biology models, deepening our systemic disease understanding, and driving our first therapeutic programs towards clinical trials to deliver tangible impact for patients.”
Max Jaderberg, the company’s president, said the interdisciplinary teams were “routinely solving complex biological problems that have stalled traditional research for decades,” and that the firm was “translating our discoveries directly into potential life-changing medicines.”
Neil Mehta, founder and managing partner of Greenoaks, called discovering new medicines “an optimization challenge of almost infinite scale,” and said the firm was “proud to partner with them on this essential mission.” Konstantine Buhler, a partner at Sequoia Capital, said: “Using AI to improve human health is one of the most important challenges of our generation.” Those are the backers’ characterisations of the work, not independent assessments of the pipeline.
Isomorphic Labs was founded in 2021 and is headquartered in London, with offices in Cambridge, Massachusetts, and Lausanne, Switzerland.
The announcement sits in a wider run of AI-for-biology funding and drug-design work TSN has covered, including a $1.8 billion public-sector push for AI-ready biological data and a Deep Origin and BioAge collaboration on AI drug discovery. An earlier TSN post recorded talks that put a much higher figure on Isomorphic Labs. That figure is not in today’s announcement and is not adopted here.
A Series C announcement is not a valuation
The only equity figure the company has put on this round is the $5 billion it says it has raised. It has not published a post-money or pre-money valuation, a share price, or a percentage for any investor, including Alphabet, whose role is described only as “continued significant investment.” Treating the $5 billion as a valuation, or inferring one from the earlier talks, would go beyond the texts published on 17 November.
Those earlier talks, recorded in a previous TSN post, are a separate, unconfirmed thread. They are useful context for readers who saw a much larger number attached to the company. They are not a term of this Series C, and the company has not restated or withdrawn them in the new release because it has not mentioned them at all. The right place for that earlier figure is the earlier post, not this one, except as a pointer.
The scientific claims are likewise the company’s own. Positive preclinical results in oncology and immunology, and the statement that this is “setting the stage for clinical entry,” describe a pipeline that is not, in this announcement, already in human trials. Hassabis’s wording is that the new capital will help drive “first therapeutic programs towards clinical trials.” That is a destination, not a claim that those trials have begun.
The investor list is full, and it is also the end of the official financial disclosure. Until the company or a filing publishes a valuation or a cap table, the public record of this round is the $5 billion raised, the co-leads, Alphabet’s continued participation, and a product plan built around IsoDDE.
Sources
- “Isomorphic Labs announces $5 Billion Series C funding,” PR Newswire, 17 November 2026, 12:17 GMT
- “Isomorphic Labs announces Series C investment round,” Isomorphic Labs, 17 November 2026
Get TSN’s biggest tech stories, explained.
News and insights across AI, tech, crypto and cybersecurity. Every source linked. Unsubscribe anytime.
Get the newsletterRelated stories
- Firmus Pulls Its ASX IPO as Isomorphic Labs Eyes a $40bn Valuation
- Biohub, DOE and NIH Lead $1.8bn Push for AI-Ready Biology Data
- Deep Origin and BioAge Labs Team Up on AI Drug Discovery, With First Hits Confirmed in the Lab
Follow @tsnmediahub on X for breaking AI news as it happens.
Follow on X
